US FDA Vaccine Approvals Set Up CDC Votes On Merck’s Capvaxive, Moderna’s mResvia

Advisory Committee on Immunization Practices expected to vote 26-28 June on use of Merck’s 21-valent pneumococcal vaccine, Moderna’s mRNA vaccine for RSV, and an expanded age range for GlaxoSmithKline’s Arexvy RSV vaccine.

Vaccine for older woman — ACIP will consider two newly approved vaccines for adults and one with an expanded indication. • Source: Shutterstock

A lively vaccine pipeline has helped to smooth and speed the transition between US Food and Drug Administration approval and the Centers for Disease Control and Prevention’s subsequent recommendations for use, with recent approvals of three vaccine applications neatly meeting the CDC’s expectations for the 26-28 June session of its Advisory Committee on Immunization Practices.

Key Takeaways

FDA approvals of Merck’s Capvaxive, Moderna’s mResvia and a new claim for GSK’s Arexvy came in time for votes at CDC vaccine committee’s 26-28 June meeting.

The FDA approvals came in the well-trod fields of pneumococcal and respiratory syncytial virus vaccines, where CDC recommendations are already...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Don’t Look Back: US FDA AdComm Offers No Flexibility For Rexulti’s Post Hoc Bid In PTSD

19 Jul 2025

• By Bridget Silverman

The US FDA's Psychopharmacology Advisory Committee emphasized high standards over regulatory flexibility while turning down Otsuka's brexpiprazole plus serotonin for post-traumatic stress disorder based on conflicting Phase III trials and post-hoc Phase II analyses.

Sarepta Refuses To Stop Elevidys Shipments After Third Death Linked To Gene Therapy Vector

18 Jul 2025

• By Mandy Jackson

Sarepta knew about the death in a Phase I trial of SRP-9004 for LGMD when it recently revealed a restructuring plan, but did not disclose the event. The now-discontinued gene therapy candidate uses the same AAV vector as Elevidys, which has been linked to two DMD patient deaths.

‘Missed Opportunity’: GSK Failed To Optimize Blenrep Dosage, US FDA Panel Says

17 Jul 2025

• By Sue Sutter

The Oncologic Drugs Advisory Committee said the benefit-risk of belantamab mafoditin for two second-line multiple myeloma indications is not favorable at the proposed dosages and raised concerns about applicability of trial results to US patients.